DYN - Dyne Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$37.40
DETAILS
HIGH:
$60.00
LOW:
$23.00
MEDIAN:
$38.50
CONSENSUS:
$37.40
UPSIDE:
115.31%
About Dyne Therapeutics, Inc. (https://www.dyne-tx.com)
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| John G. Cox | Chief Executive Officer, President & Director | 1963 | $1,138,975 USD |
| Johanna Friedl-Naderer | Chief Commercial Officer | 1968 | $842,754 USD |
| Douglas Kerr | Chief Medical Officer | 1967 | $748,065 USD |
| Oxana Beskrovnaya | Chief Innovation Officer | 1961 | $740,475 USD |
| Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer | 1968 | $726,892 USD |
| Vikram Ranade | Chief Business Officer | – | $662,344 USD |
| Axel Wiest | Senior VP and Head of Portfolio Strategy & Operations | – | – |
| Daniel Wilson | Senior Vice President & Head of Legal | 1972 | – |
| Debra Feldman | Chief Regulatory Affairs Officer | 1971 | – |
| James Bilotta | Chief Digital & Information Officer | – | – |
| Jose Juves | Chief Corporate & Patient Affairs Officer | – | – |
| Lucia Celona | Chief Human Resource Officer | 1966 | – |
| Monica Fay | Chief Medical Affairs Officer | – | – |
| Rajesh Manchanda | Chief Technical Officer | 1967 | – |